Beyond Steroids: A New Approach to Treating AD in Sensitive Sites
Atopic dermatitis (AD) on the eyelids, face, neck, hands, intertriginous areas, and genitals has been notoriously hard to treat, particularly given the limitations and safety concerns surrounding topical corticosteroids in these sensitive spots. However, the emergence of advanced topical therapies, including the Janus kinase (JAK) inhibitor ruxolitinib (Opzelura, Incyte), has reshaped the AD treatment landscape. Raj Chovatiya, MD, PhD, MSCI, Associate Professor of Medicine at Rosalind Franklin University of Medicine and Science Chicago Medical School in North Chicago, IL, and Founder and Director of the Center for Medical Dermatology + Immunology Research in Chicago, IL, and Melodie Young, MSN, A/GNP-C, a Dermatology Nurse Practitioner at Mindful Dermatology in Dallas, TX, reflect on the evolution of these therapies and the shifting paradigm in the management of AD.
About This Educational Video Series
This educational video series provides expert commentary on the current treatment landscape for patients with atopic dermatitis.